Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 5/20 | 0.50 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.50 |
| ▸ | PLK1 | P53350 | 9/20 | 0.48 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400703 | 0.87 | PLK1 (0.51) | MARK3MARK4PLK1MAPK7BRD4 | |
| SCHEMBL2396957 | 0.86 | PLK1 (0.47) | MARK3MARK4PLK1MAPK7BRD4 | |
| SCHEMBL2396937 | 0.86 | MARK3 (0.59) | MARK3MARK4PLK1BRD4BRDT | |
| SCHEMBL2396517 | 0.84 | PLK1 (0.49) | MARK3MARK4PLK1MAPK7BRD4 | |
| SCHEMBL2395765 | 0.84 | PLK1 (0.52) | MARK3MARK4PLK1MAPK7BRD4 | |
| SCHEMBL2396655 | 0.84 | PIK3CA (0.50) | MARK3MARK4PLK1BRD4BRDT | |
| SCHEMBL2399376 | 0.84 | PLK1 (0.51) | MARK3MARK4PLK1MAPK7BRD4 | |
| SCHEMBL2396972 | 0.83 | PLK1 (0.54) | PLK1BRD4BRDT | |
| SCHEMBL9945383 | 0.83 | PLK1 (0.53) | MARK3MARK4PLK1MAPK7BRD4 | |
| SCHEMBL4986201 | 0.82 | PLK1 (0.46) | MARK3MARK4PLK1BRD4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480550-B1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-8394952-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394952-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394952-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120271045-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120271045-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120149898-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100190765-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190765-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190765-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7622463-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622463-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622463-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120271045-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | DCK, MAP3K5, MAP3K1 | MARK3 378/4885MARK4 336/4885PLK1 42/4885 |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP4K2 | MARK3 123/4885MARK4 133/4885PLK1 89/4885 |
| US-20140038935-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K5, MAP4K2 | MARK3 123/4885MARK4 133/4885PLK1 89/4885 |
| US-20120149898-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K5, MAP4K2 | MARK3 123/4885MARK4 133/4885PLK1 89/4885 |
| US-20100190765-A1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K5, MAP4K2 | MARK3 123/4885MARK4 133/4885PLK1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.